Garcinia Cambogia for Type 2 Diabetes

Verdict: Does not work for type 2 diabetes

Garcinia cambogia (hydroxycitric acid) does not improve blood sugar in type 2 diabetes, and major diabetes authorities recommend against using it for glycemic control. It also carries a documented liver-toxicity safety concern.

D 🔴 D Counter-Evidence Disputed

🔬Why this grade7-layer evidence engine

Direct evidence in type 2 diabetes is essentially absent and points away from benefit. The only T2D trial is a small acute study of intraduodenal hydroxycitrate (PMID 26792024), where in the 8 diabetic participants HCA had no effect on blood glucose, insulin, GIP, or GLP-1. A 2025 meta-analysis of 9 randomized trials (PMID 39943939, n=444) enrolled no people with diabetes and found no significant change in fasting blood sugar (WMD +1.02 mg/dL) or insulin (WMD -0.12 mU/L), with no HbA1c outcome poolable.

More concerning, in that meta-analysis the obesity subgroup (BMI >=30) showed higher fasting glucose and insulin rather than improvement, a signal directly relevant to the obesity-diabetes overlap. Weight-loss data offer no rescue: an earlier meta-analysis (PMID 21197150) found only a trivial -0.88 kg effect, far too small to expect meaningful glycemic benefit.

Regulators and clinicians reinforce the negative verdict. The American Diabetes Association's Standards of Care explicitly states that herbs and spices are not recommended for glycemic benefit, and Cleveland Clinic would not recommend over-the-counter fat burners. On safety, the US FDA recalled all garcinia-containing Hydroxycut products over liver-injury reports, and the supplement carries a theoretical low-blood-sugar interaction risk with diabetes medications. The evidence is graded counter-evidence and disputed.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.35
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Disputed
Confidence
73%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.15
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.40
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.35
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled tr…
PMID: 26792024 2016 RCT (double-blind) n = 20
Finding: In T2D subgroup (n=8), HCA had no effect on blood glucose, insulin, GIP, or GLP-1 vs control; only plasma glucagon was higher with HCA (p=0.04). Modest glycemia reduction and GIP/glucagon rise seen only in healthy subjects.
Effect size: No significant glycemic difference in T2D
View on PubMed
The effects of Garcinia cambogia on glycaemic control and liver enzymes in adults: a systematic review and meta-analysis of randomised controlled trials
PMID: 39943939 2025 統合分析 n = 444
Finding: No significant overall effect on FBS (WMD 1.02 mg/dL, 95% CI -1.29 to 3.33) or insulin (WMD -0.12 mU/L, 95% CI -1.50 to 1.25). Subgroups: females had increased insulin; BMI≥30 showed increased both FBS and insulin; duration >8 weeks reduced insulin. No HbA1c synthesis; no T2D-specific trials in pool.
🟢 High quality Effect size: WMD FBS +1.02 mg/dL (NS); WMD insulin -0.12 mU/L (NS)
View on PubMed
Effect of orlistat alone or in combination with Garcinia cambogia on visceral adiposity index in obese patients (Al-Kuraishy)
PMID: 27757272 2016 隨機對照試驗 n = 99
Finding: G. cambogia alone reduced VAI; orlistat had stronger cardiometabolic effects; combination superior on VAI and cardiometabolic profile vs baseline. Reported in obese non-diabetic males, not T2D; HbA1c not reported. Dose used is far below typical 1500–2800 mg/day Garcinia studies.
View on PubMed
The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials (Onakpoya)
PMID: 21197150 2011 統合分析
Finding: Small statistically significant weight-loss effect (MD -0.88 kg, 95% CI -1.75 to -0.00) of unclear clinical relevance; GI AEs more common with HCA. Did not assess T2D glycemic endpoints but contextually shows weight effects insufficient to expect meaningful T2D benefit.
Academic Effect size: MD -0.88 kg (95% CI -1.75 to -0.00)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
the FDA recalled all Hydroxycut products and mandated removal of products already in distribution source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
藤黃果(Garcinia cambogia)果實可供為茶包、膳食調理包原料或經萃取後作為飲料、錠狀、膠囊狀、粉末狀、顆粒狀等食品之原料,並有限量,以所含之羥基檸檬酸(HCA, hydroxycitric acid)計,每日食用限量為 1,500 mg 以下。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Against
Supplementation with micronutrients (e.g., vitamins and minerals, such as magnesium or chromium) or herbs or spices (e.g., cinnamon and aloe vera) is not recommended for glycemic benefits. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-garcinia-cambogia-001 繁體中文版 →